Unknown

Dataset Information

0

Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer.


ABSTRACT: Tamoxifen(TAM) is one of the most effective endocrine treatment for estrogen receptor(ER)-positive breast cancer, however drug resistance greatly limits benefit of it. Our purpose is to uncover the role of Beclin 1 in tamoxifen resistance and prognosis of ER positive breast cancer. We established a tamoxifen resistant ER-positive breast cancer cell subline MCF-7R presenting with higher Beclin 1 and human epidermal growth factor receptor 2(HER2) levels than MCF-7. Silencing Beclin 1 decreased levels of HER2 and significantly promoted TAM sensitivity of MCF-7 and MCF-7R in vitro. Overexpression of HER2 could reverse TAM sensitivity, which was formerly increased in Beclin 1 downregulated cell. Beclin 1 level was not only positively correlated with level of HER2 but also negatively correlated with overall survival of ER-positive breast cancer patients. Using bioinformatic methods, Beclin 1 mRNA was found to be negatively correlated with overall survival in breast cancer patients receiving TAM treatment. This study indicated for the first time that lower HER2 expression by Beclin 1 downregulation contributes to alteration of tamoxifen sensitivity and low Beclin 1 predicts favorable outcome in ER-positive breast cancer.

SUBMITTER: Gu Y 

PROVIDER: S-EPMC5581020 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer.

Gu Yu Y   Chen Tianxiang T   Li Guangliang G   Xu Cong C   Xu Zhenzhen Z   Zhang Jing J   He Kuifeng K   Zheng Linyan L   Guan Zhonghai Z   Su Xinyun X   Cao Jiang J   Teng Lisong L  

Oncotarget 20160804 32


Tamoxifen(TAM) is one of the most effective endocrine treatment for estrogen receptor(ER)-positive breast cancer, however drug resistance greatly limits benefit of it. Our purpose is to uncover the role of Beclin 1 in tamoxifen resistance and prognosis of ER positive breast cancer. We established a tamoxifen resistant ER-positive breast cancer cell subline MCF-7R presenting with higher Beclin 1 and human epidermal growth factor receptor 2(HER2) levels than MCF-7. Silencing Beclin 1 decreased lev  ...[more]

Similar Datasets

| S-EPMC7961649 | biostudies-literature
| S-EPMC4396031 | biostudies-literature
| S-EPMC7482812 | biostudies-literature
| S-EPMC2688939 | biostudies-literature
| S-EPMC7050981 | biostudies-literature
| S-EPMC4964104 | biostudies-literature
| S-EPMC3326451 | biostudies-literature
| S-EPMC2634679 | biostudies-literature
| S-EPMC4964078 | biostudies-literature
| S-EPMC10358080 | biostudies-literature